One-year incidence of low libido in women using levonorgestrel subdermal implant as contraception. Cohort study. Armenia, Colombia, 2014-2019
DOI:
https://doi.org/10.18597/rcog.3520Abstract
Objective: To determine the incidence of low libido in women using the levonorgestrel (LNG) subdermal implant for contraception after 12 months and to identify other adverse effects. Materials and methods: Cohort study that included women over the age of 18, with no children or prior gestations and in a stable relationship, with an LNG implant inserted at least three months before in a private teaching hospital in Armenia (Quindío), Colombia, between 2014 and 2019. Women with a history of sexual dysfunction, sexually transmitted infections in the past six months, weighing more than 89 kg and difficult to follow were excluded. Consecutive sampling was used. The characteristics of the study population were described, the cumulative incidence of low libido and the adverse effects related to the LNG subdermal implant after 12 months of follow-up were estimated. The tool used was the Female Sexual Dysfunction Index (FSFI). Descriptive statistics were applied. Results: The participants were 238 women with a mean age of 24.69 (SD ± 5.82) years. An 18.82% incidence of low libido was found. In 60.25% of the women were diagnosed with low libido in the first 6 months of follow-up. Adverse effects manifested as early as 3 months after the insertion of the implant, the most frequent being irregular bleeding (62.34%), followed by amenorrhea (38.91%) and weight gain (33.89%). Conclusions: It is important for practitioners and users to become aware of the presence of low libido disorder and the adverse events that may occur with the use of the levonorgestrel subdermal implant. Future research is required to confirm these findings and the underlying physiological cause.
Author Biography
Franklin José Espitia De La Hoz, Hathor, Clínica Sexológica, Armenia (Colombia).
Director Científico, Hathor, Clínica Sexológica, Armenia (Colombia).
References
Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, et al. Hypoactive Sexual Desire Disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) Expert Consensus Panel Review. Mayo Clin Proc. 2017; 92(1):114-28. https://doi.org/10.1016/j.mayocp.2016.09.018
Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual Problems and Distress in United States Women: Prevalence and Correlates. Obstet Gynecol. 2008; 112(5):970-8. https://doi.org/10.1097/AOG.0b013e3181898cdb
Espitia-De La Hoz FJ. Prevalence and characterisation of sexual dysfunctions in women, in 12 Colombian cities, 2009-2016. Rev Colomb Obstet Ginec. 2018; 69(1):9-21. https://doi.org/10.18597/rcog.3035
Hayes RD, Dennerstein L, Bennett CM, Koochaki PE, Leiblum SR, Graziottin A. Relationship between hypoactive sexual desire disorder and aging. Fertil Steril. 2007; 87(1):107-12. https://doi.org/10.1016/j.fertnstert.2006.05.071
West SL, D’Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med. 2008; 168(13):1441-9 https://doi.org/10.1001/archinte.168.13.1441
Abdo CH, Valadares AL, Oliveira WM Jr, Scanavino MT, Afif-Abdo J. Hypoactive sexual desire disorder in a population-based study of Brazilian women: associated factors classified according to their importance. Menopause. 2010; 17(6):1114-21. https://doi.org/10.1097/gme.0b013e3181e19755
Clayton AH, Goldfischer ER, Goldstein I, Derogatis L, Lewis-D’Agostino DJ, Pyke R. Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med. 2009; 6(3):730-8. https://doi.org/10.1111/j.1743-6109.2008.01153.x
Sills T, Wunderlich G, Pyke R, Segraves RT, Leiblum S, Clayton A, et al. The Sexual Interest and Desire Inventory—Female (SIDI-F): item response analyses of data from women diagnosed with hypoactive sexual desire disorder. J Sex Med 2005; 2:801–18. https://doi.org/10.1111/j.1743-6109.2005.00146.x
Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000; 26(2):191-208. https://doi.org/10.1080/009262300278597
Rosen RC. Assessment of female sexual dysfunction: review of validated methods. Fertil Steril. 2002; 77 Suppl 4:S89-93. https://doi.org/10.1016/s0015-0282(02)02966-7
Vallejo-Medina P, Pérez-Durán C, Saavedra-Roa A. Translation, Adaptation, and Preliminary Validation of the Female Sexual Function Index into Spanish (Colombia). Arch Sex Behav. 2018; 47(3):797-810. https://doi.org/10.1007/s10508-017-0976-7
Pérez-Herrezuelo I, Hita-Contreras F, Martínez-Amat A, Aibar-Almazán A, Cruz-Díaz D, Wangensteen R, et al. The female sexual function index: reliability and validity in Spanish postmenopausal women. Menopause. 2019; 26(4):401-8. https://doi.org/10.1097/GME.0000000000001305
Casado-Espada NM, de Alarcón R, de la Iglesia-Larrad JI, Bote-Bonaechea B, Montejo ÁL. Hormonal Contraceptives, Female Sexual Dysfunction, and Managing Strategies: A Review. J Clin Med. 2019; 8(6):908. https://doi.org/10.3390/jcm8060908
Espitia-De La Hoz FJ. Educación y asesoramiento sexual para hombres y mujeres. Bogotá. Editorial Nomos S.A. Primera edición. 2018; 8(1):99-100.
Espitia-De La Hoz FJ, Orozco-Gallego H. Alteration of the sexual response cycle in women using combined oral contraceptives. Salud Uninorte. Barranquilla (Col.) 2018; 34 (2):430-42. https://doi.org/10.14482/sun.34.2.613.94
Bjelica A, Kapamadzija A, Maticki-Sekulic M. Hormones and female sexuality. Med. Pregl. 2003; 56(9-10):446-50. https://doi.org/10.2298/MPNS0310446B
Sanders SA, Graham CA, Bass JL, Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception. 2001; 64(1):51–8. https://doi.org/10.1016/s0010-7824(01)00218-9
Black A, Guilbert E, Costescu D, Dunn S, Fisher W, Kives S, et al. No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception. J. Obstet. Gynaecol. Canada 2017; 39(4):229–68.e5. https://doi.org/10.1016/j.jogc.2016.10.005
Smith NK, Jozkowski KN, Sanders SA. Hormonal contraception and female pain, orgasm and sexual pleasure. J. Sex. Med. 2014; 11(2):462–70. https://doi.org/10.1111/jsm.12409
Casey PM, MacLaughlin KL, Faubion SS. Impact of Contraception on Female Sexual Function. J. Women’s Heal. 2017; 26(3):207-13. https://doi.org/10.1089/jwh.2015.5703
Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review. Eur J Contracept Reprod Health Care. 2013; 18(1):27-43. https://doi.org/10.3109/13625187.2012.728643
Boozalis A, Tutlam NT, Chrisman Robbins C, Peipert JF. Sexual Desire and Hormonal Contraception. Obstet Gynecol. 2016; 127(3):563-72. https://doi.org/10.1097/AOG.0000000000001286
Wan LS, Stiber A, Lam LY. The levonorgestrel two-rod implant for long-acting contraception: 10 years of clinical experience. Obstet Gynecol. 2003; 102(1):24- 6. https://doi.org/10.1016/s0029-7844(03)00482-4
Committee on Practice Bulletins-Gynecology, Long-Acting Reversible Contraception Work Group. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol. 2017; 130(5):e251-e269. https://doi.org/10.1097/AOG.0000000000002400
Sivin I, Wan L, Ranta S, Alvarez F, Brache V, Mishell DR Jr, et al. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. Contraception. 2001; 64(1):43-9. https://doi.org/10.1016/s0010-7824(01)00226-8
Critchley HO, Bailey DA, Au CL, Affandi B, Rogers PA. Immunohistochemical sex steroid receptor distribution in endometrium from long-term subdermal levonorgestrel users and during the normal menstrual cycle. Hum Reprod. 1993; 8(10):1632-9. https://doi.org/10.1093/oxfordjournals.humrep.a137904
Curtis KM. Safety of implantable contraceptives for women: data from observational studies. Contraception. 2002; 65(1):85-96. https://doi.org/10.1016/s0010-7824(01)00291-8
Sivin I. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. Drug Saf. 2003; 26(5):303-35. https://doi.org/10.2165/00002018-200326050-00002
Aisien AO. Contraception with levonorgestrel subdermal implants (Norplant) in Benin-City, Nigeria: a 12-year review. Afr J Reprod Health. 2007; 11(1):90-7. https://doi.org/10.2307/30032491
Brache V, Faundes A, Alvarez F, Cochon L. Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception. 2002; 65(1):63-74. https://doi.org/10.1016/s0010-7824(01)00289-x
Hickey M, d’Arcangues C. Vaginal bleeding disturbances and implantable contraceptives. Contraception. 2002; 65(1):75-84. https://doi.org/10.1016/s0010-7824(01)00292-x
Fraser IS, Tiitinen A, Affandi B, Brache V, Croxatto HB, Diaz S, et al. Norplant consensus statement and background review. Contraception. 1998; 57(1):1-9. https://doi.org/10.1016/s0010-7824(97)00200-x
Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. Contraception. 1998; 58(6 Suppl):99S-107S. https://doi.org/10.1016/s0010-7824(98)00123-1
Sivin I. Contraception with NORPLANT® implants, Human Reproduction. Contraception 1994; 9(10): 1818–26. https://doi.org/10.1093/oxfordjournals.humrep.a138341
Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception. 1995; 52(4):215-9. https://doi.org/10.1016/0010-7824(95)00189-h
Cullins VE, Blumenthal PD, Remsburg RE, Huggins GR. Preliminary experience with Norplant in an innercity population. Contraception. 1993; 47(2):193-203. https://doi.org/10.1016/0010-7824(93)90091-k
Sivin I, Alvarez F, Mishell DR Jr, Darney P, Wan L, Brache V, et al. Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic. Contraception. 1998; 58(5):275-82. https://doi.org/10.1016/s0010-7824(98)00112-7
How to Cite
Downloads
Downloads
Published
Issue
Section
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
